Do Microplastic Removal Supplements Work? Evidence Review

What counts as proof that a supplement works?

“Binds plastic,” “increases particles in stool” and “removes microplastics from the body” are different claims. A material can associate with a particle in a test tube without preventing absorption in a person. More particles in one stool sample can reflect a change in transit or recent intake without showing that particles already in tissue were cleared. A useful health claim requires a reliable human endpoint and an appropriate comparison group.

We therefore separated the evidence into controlled laboratory binding, cell-model interaction, animal evidence, short human proof of concept, human excretion, body-burden change and clinical outcomes. This avoids turning an early mechanism into a detox conclusion.

What the Qi601 study actually found

The September 2026 Frontiers in Microbiology paper tested Qi601, a non-viable preparation made from biofilm-cultured Limosilactobacillus fermentum LfQi6. In the main sequestration experiments, the researchers used fluorescent 100 nm polystyrene nanoplastic spheres. Qi601 reduced the fluorescence remaining in the supernatant by about 92% after a sequential simulated-digestion protocol. That measurement indicates depletion from the liquid phase; the paper notes that it was not a direct count of particles captured in the pellet.

In Caco-2 intestinal-cell experiments, Qi601 reduced surface-associated and intracellular particle fluorescence in several protection and post-exposure conditions. These are useful mechanism results, but Caco-2 is a colorectal cancer-derived cell line. The cultures were not tested as barrier-competent monolayers, and the paper says the findings do not establish intestinal barrier function.

Other limits matter for real-world claims. Most experiments used one polymer, one spherical particle model and concentrations chosen for detection. Pancreatin was omitted from the adapted digestion protocol. Imaging analysis was not blinded, and one commercial production lot was tested. The results do not establish performance across the varied sizes, shapes and polymers people encounter.

Was the gum experiment a human clinical trial?

No. The paper describes a qualitative, single-subject proof-of-concept experiment. One adult completed gum-only and gum-plus-Qi601 conditions, and the saliva was expectorated for microscopy and spectroscopy. The researchers saw gum-derived particles within or near Qi601 agglomerates and reported fewer background-adjusted rubber-class particles in the gum-plus-Qi601 saliva sample.

That is direct human-mouth evidence of physical association under one exploratory procedure. It does not show how much plastic was captured, whether the result repeats across people, whether an oral dose works elsewhere in the digestive tract, whether bound particles leave in stool, or whether exposure or body burden falls. The authors explicitly state that the experiment did not assess dose response, safety, biodistribution, gastrointestinal elimination or clinical efficacy.

The study was funded by Quorum Innovations, which provided the material. All authors were company employees, and two disclosed that they were officers, equity holders and inventors of company-owned intellectual property. That does not invalidate the data, but independent replication is especially important before using the paper to make a purchase or health decision.

What did the chitosan supplement pilot show?

The 2025 Foods study is the closest published human evidence for a supplement and fecal particle output. Ten healthy volunteers ate a standardized meal in two phases one week apart. In the second phase, everyone took 0.8 g of chitosan derived from red swamp crayfish immediately before the meal. The researchers reported a mean of 656 particles in the next stool sample without chitosan and 965 with chitosan, across the measured 20–500 µm range.

This is a preliminary signal, not proof of detoxification. Everyone received the no-supplement phase first and chitosan phase second; the abstract does not describe random assignment or a placebo. It sampled one post-meal bowel movement, enrolled only 10 people and did not measure blood, organs, longer-term balance or health outcomes. Greater fecal output after an oral binder could represent intercepted dietary particles; it does not demonstrate removal of particles stored in tissue.

Does GRAS mean Qi601 is approved or proven safe?

No. The FDA record for GRN 988 says the agency had no questions about the notifier's conclusion that the live LfQi6 source strain is generally recognized as safe for specified food uses at stated levels. The listed uses include dairy products, cereals, drinks, confections and chewing gum. That record predates the microplastic paper and does not evaluate whether Qi601 removes microplastics.

The FDA explains that it does not approve dietary supplements for safety and effectiveness before they are sold. The Qi601 paper did not test human safety, dose response or repeated use. A source organism's GRAS record therefore cannot substitute for evidence about the finished product's efficacy, dosing or long-term use.

What does “postbiotic” mean here?

The ISAPP consensus definition describes a postbiotic as a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host. Qi601 contains non-viable intact bacterial cells in aggregates. Calling a preparation a postbiotic describes what it is intended to be; the word itself does not prove a benefit for microplastic exposure.

Live probiotics also do not necessarily colonize the gut, and evidence from one strain cannot be transferred to another. The registered PD01 probiotic trial, the Qi601 postbiotic paper and mouse studies of other strains are separate interventions with different endpoints. Our ClinicalTrials.gov search for Qi601 did not identify a registered Qi601 ingestion trial in the record reviewed October 7, 2026.

Should you buy a microplastic detox supplement?

The evidence is too early to recommend one for microplastic removal. Qi601 has a plausible physical-sequestration mechanism and a peer-reviewed preclinical paper, but no controlled human ingestion study. Chitosan has a small human fecal-output signal, but no replicated evidence that it lowers total body burden. Neither has shown a clinical benefit from changing microplastic exposure.

If you are considering any supplement, discuss it with a clinician or pharmacist who knows your conditions, medicines and allergies. That is particularly relevant for chitosan made from shellfish and for any product taken around medicines. Avoid interpreting “clinically studied,” a patent, a GRAS notice or a laboratory binding percentage as evidence that a product detoxifies the human body.

For adjacent evidence, see our reviews of the completed PD01 trial and interim preprint, the kimchi-derived strain experiments, and what is known about persistence and clearance.

What a convincing next study would measure

• Randomization and placebo control: with the protocol and primary endpoint registered before results are known.
• Validated particle analysis: including blanks, contamination controls, chemical identification, size limits and recovery tests.
• A relevant human endpoint: repeated fecal measurements plus a justified measure of absorption or body burden, rather than one saliva image or one bowel movement.
• Realistic exposures: multiple polymers, shapes and doses that reflect food and water rather than only fluorescent polystyrene spheres.
• Safety and interactions: adverse events, medication timing, nutrient effects and repeated-use follow-up.
• Independent replication: by investigators without a financial interest in the product.

Use the App

Check the evidence level before the detox claim

MicroPlastics separates test-tube binding, animal evidence and human outcomes so an early mechanism is not mistaken for proven removal.